Platelet-Derived Growth Factor alpha Receptor

A PDGF receptor that binds specifically to both PDGF-A chains and PDGF-B chains. It contains a protein-tyrosine kinase activity that is involved in SIGNAL TRANSDUCTION.

Also Known As:

Receptor, Platelet-Derived Growth Factor alpha; CD140a Antigen; PDGFR2; PDGFRalpha; Antigen, CD140a; Platelet Derived Growth Factor alpha Receptor; Antigens, CD140a; CD140a Antigens; PDGF alpha Receptor; PDGF-R-alpha; Receptor, PDGF alpha

Networked: 224 relevant articles (4 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sulzbacher, Irene: 4 articles (12/2010 - 01/2003)
2.	Kazlauskas, Andrius: 4 articles (05/2010 - 02/2002)
3.	Galle, Peter R: 4 articles (03/2010 - 03/2008)
4.	Gockel, Ines: 4 articles (03/2010 - 03/2008)
5.	Moehler, Markus: 4 articles (03/2010 - 03/2008)
6.	Schimanski, Carl C: 4 articles (03/2010 - 03/2008)
7.	Loizos, Nick: 4 articles (02/2010 - 03/2005)
8.	Toepoel, Mascha: 4 articles (07/2009 - 12/2002)
9.	van Zoelen, Everardus J J: 4 articles (07/2009 - 12/2002)
10.	Nistér, M: 4 articles (08/2006 - 11/2000)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2010 - "Daily treatment of 6-month-old DEN-exposed beta-cat KO with PDGFRalpha inhibitor dramatically reduced tumor numbers and size. " 03/01/2005 - "These data suggest that 3G3 may be useful for the treatment of tumors that express PDGFRalpha." 11/01/2009 - "Together these observations implicate PDGFRA and KIT as potential oncogenes in NSCLC, but further study is needed to define the specific characteristics of those tumors that could respond to PDGFRalpha/KIT inhibitors." 04/01/2009 - "These studies demonstrate that combined inhibition of PDGFRalpha and -beta results in markedly decreased tumor growth in vivo because of impaired recruitment of periendothelial cells." 07/01/2011 - "The present review evaluates the most important parameters in GIST: epidemiology, principal clinical presentations, histopathological patterns of GIST with differential diagnosis and Fletcher's and Miettinen's risk classification, immunohistochemistry, prognostic factors, c-KIT and PDGFRalpha mutations and treatment of this tumor. "
2.	Pdgfra-Associated Chronic Eosinophilic Leukemia 11/01/2008 - "[FIP1L1/PDGFRalpha fusion gene-negative chronic eosinophilic leukemia with t(5;12)(q31;p13): a case report and review of literatures]." 11/12/2006 - "The diagnosis of chronic myeloid leukemia and certain types of chronic eosinophilic leukemia are based on the detection of fusion genes (in chronic myeloid leukemia the BCR/ABL fusion gene, and in chronic eosinophilic leukemia the FIP1L1-PDGFRalpha gene). " 04/01/2008 - "PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment." 09/15/2008 - "FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome." 05/01/2005 - "[Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. "
3.	Hyperalgesia 10/26/2005 - "Moreover, thermal hyperalgesia and tactile allodynia induced by thrombin in normal mice were virtually eliminated by intrathecal pretreatment with PDGFRalpha/Fc. " 10/26/2005 - "Thermal hyperalgesia and tactile allodynia induced by sciatic nerve ligation were also suppressed by repeated intrathecal injection of either the PDGF alpha receptor (PDGFRalpha)/Fc chimera protein or the PDGFR-dependent tyrosine kinase inhibitor AG17 [(3,5-di-tert-butyl-4-hydroxybenzylidene)-malononitrile]. "
4.	Glioma (Gliomas) 06/20/2010 - "PDGFRalpha may be a useful target for pediatric HGG, including diffuse pontine gliomas." 06/20/2010 - "PDGFRA was the predominant target of focal amplification in childhood HGG, including diffuse intrinsic pontine gliomas, and gene expression analyses supported an important role for deregulated PDGFRalpha signaling in pediatric HGG. " 05/01/2010 - "Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping." 04/09/2008 - "Irrespective of the grade and morphological diagnosis of gliomas, glioma cells concomitantly expressed PDGFRalpha, A2B5, O4, CD44 and GFAP. " 04/09/2008 - "Six low-grade and 17 high-grade glioma specimens were flow-cytometrically analyzed for markers characteristics of stem cells (CD133); glial progenitors (PDGFRalpha, A2B5, O4, and CD44); and late oligodendrocyte progenitors (O1). "
5.	Prostatic Neoplasms (Prostate Cancer) 05/15/2010 - "Our studies show that this truncated PDGFRalpha is able to restore bone-metastatic potential of prostate cancer cells as effectively as the full-length form of the receptor." 01/22/2009 - "Interestingly, prostate cancer cells expressing the alpha-receptor for platelet-derived growth factor (PDGFRalpha) progress during early-stages of skeletal dissemination, whereas cells expressing lower levels or lacking this receptor fail to survive after extravasation in the bone marrow. " 01/22/2009 - "In conclusion, our results strongly implicate PDGFRalpha in prostate cancer bone tropism through its promotion of survival and progression of early-metastatic foci, providing ground for therapeutic strategies aimed at preventing or containing the initial progression of skeletal metastases in patients affected by prostate adenocarcinoma." 01/22/2009 - "Finally, functional blockade of human PDGFRalpha on prostate cancer cells utilizing a novel humanized monoclonal antibody -- soon to undergo phase-II clinical trials -- significantly impairs the establishment of early skeletal metastases. " 05/15/2010 - "We previously showed that bone-metastatic prostate cancer cells exposed to human bone marrow respond by activation of cell survival pathways, such as phosphoinositide 3-kinase/Akt, and that these events are mediated by the alpha-receptor for platelet-derived growth factor (PDGFRalpha). "

Related Drugs and Biologics

1.	Imatinib Mesylate (Gleevec)
2.	Thrombin
3.	Platelet-Derived Growth Factor
4.	Antibodies
5.	Transforming Growth Factors (Transforming Growth Factor)
6.	Peptides (Polypeptides)
7.	Insulin-Like Growth Factor II (Somatomedin A)
8.	platelet-derived growth factor AB
9.	Formaldehyde (Formol)
10.	Insulin-Like Peptides

Related Therapies and Procedures

1.	Ligation
2.	Therapeutics
3.	Neoadjuvant Therapy
4.	Spinal Injections
5.	Drug Therapy (Chemotherapy)